Northern Trust Corp Immuneering Corp Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Immuneering Corp stock. As of the latest transaction made, Northern Trust Corp holds 176,005 shares of IMRX stock, worth $251,687. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,005

Previous 183,927 4.31%

Holding current value

$251,687

Previous $1.35 Million 62.4%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.91 - $7.32 $15,131 - $57,989	-7,922 Reduced 4.31%	176,005 $508,000
Q4 2023 Feb 13, 2024	SELL	$4.84 - $8.44 $7,410 - $12,921	-1,531 Reduced 0.83%	183,927 $1.35 Million
Q3 2023 Nov 13, 2023	BUY	$7.21 - $10.68 $88,228 - $130,691	12,237 Added 7.06%	185,458 $1.42 Million
Q2 2023 Aug 11, 2023	BUY	$6.49 - $13.36 $882,127 - $1.82 Million	135,921 Added 364.4%	173,221 $1.76 Million
Q1 2023 May 15, 2023	BUY	$3.78 - $10.38 $9,979 - $27,403	2,640 Added 7.62%	37,300 $362,000

Q3 2022 Nov 14, 2022	BUY	$5.0 - $12.85 $94,885 - $243,854	18,977 Added 121.0%	34,660 $496,000
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $497,433 - $998,703	-127,875 Reduced 89.08%	15,683 $85,000
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $437,805 - $1.15 Million	67,667 Added 89.16%	143,558 $929,000
Q4 2021 Feb 08, 2022	BUY	$16.12 - $31.02 $52,857 - $101,714	3,279 Added 4.52%	75,891 $1.23 Million
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $1.23 Million - $2.38 Million	72,612 New	72,612 $1.93 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $37.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Immuneering Corp Transaction History